Knowde Enhanced TDS
Identification & Functionality
- Ingredient Name
- Ingredients
- Boswellia Extract, Boswellic Acid
Features & Benefits
- Labeling Claims
- Product Highlights
Clinically demonstrated to improve joint comfort and reduce a key cartilage-degrading enzyme, 5-LOXIN®, a potent Boswellia serrata extract, has become one of the best known ingredients in the joint health category. AquaLOX®, a newly developed extract – documented to have bioavailability similar to 5-LOXIN – opens up new formulation opportunities never before available. Produced using a specialized process, AquaLOX is low-dosage and watersoluble with a neutral organoleptic profile making it ideal for taste-sensitive formulations.
Now, AquaLOX has been clinically demonstrated in a PK study to be as bioavailable as 5-LOXIN, giving you the opportunity to deliver palatable joint health support across a new range of
delivery formats.- Features
- Supported by 8 pre-clinical
- & clinical studies
- Water soluble
- Neutral taste
- Low dosage
- Patent-pending
- Kosher, Halal, Gluten-Free
- Non-GMO
Applications & Uses
- Markets
Regulatory & Compliance
Technical Details & Test Data
- AQUALOX & 5-LOXIN Highlights
Consumers are looking for new ways to improve joint comfort – and new delivery forms that complement today’s lifestyles. AquaLOX® delivers the actives they are looking for and allows for creativity in your formulations – low dosage gummies, chews, shots, beverages, and more.
Product Concepts for AquaLOX Beverages Liquids Chewables Shots Gummies Stick-packs Clinical research demonstrates that AKBA-rich 5-LOXIN improves joint comfort and mobility within 7 days. Additionally, it:
- Provides significant benefits in WOMAC, VAS and LFI standardized testing methodologies for joint health
- Has been shown to significantly inhibit matrix metalloproteinase (MMP-3), an enzyme that breaks down cartilage and connective tissues
- Is well-tolerated, easy on the stomach and is is supported by extensive safety data
AquaLOX (mean ± SD) 5-Loxin (mean ± SD) AUC0-∞ (ng*hr/mL) 166.03 ± 71.46 144.21 ± 65.74 - In a RDBC crossover clinical trial, healthy adults took either 40 mg AquaLOX (31.2 mg AKBA) or 100 mg 5-LOXIN (30 mg AKBA) in a random order on separate occasions
- Results for AUC0-∞ (Area under the curve) show similar amounts of total AKBA were absorbed with each produc